PMS-SILDENAFIL R TABLET

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

SILDENAFIL (SILDENAFIL CITRATE)

Disponibbli minn:

PHARMASCIENCE INC

Kodiċi ATC:

C02KX

INN (Isem Internazzjonali):

ANTIHYPERTENSIVES FOR PULMONARY ARTERIAL HYPERTENSION

Dożaġġ:

20MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

SILDENAFIL (SILDENAFIL CITRATE) 20MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

90/100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

PHOSPHODIESTERASE TYPE 5 INHIBITORS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0136261004; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2013-09-11

Karatteristiċi tal-prodott

PRODUCT MONOGRAPH
PR
PMS-SILDENAFIL R
Sildenafil
Tablets
20 mg sildenafil (as sildenafil
citrate)
BP Standard
CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR
TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
www.pharmascience.com
DATE OF REVISION:
June 8, 2021
Submission
Control No: 252093
_pms-SILDENAFIL R Product Monograph _
_Page 2 of 55_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................3
CONTRAINDICATIONS
.............................................................................................3
WARNINGS AND PRECAUTIONS
.............................................................................4
ADVERSE
REACTIONS............................................................................................
10
DRUG INTERACTIONS
............................................................................................
15
DOSAGE AND ADMINISTRATION
.........................................................................
21
OVERDOSAGE
.........................................................................................................
22
ACTION AND CLINICAL
PHARMACOLOGY.........................................................
22
STORAGE AND STABILITY
....................................................................................
26
SPECIAL HANDLING INSTRUCTIONS
................................................................... 26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 27
PART II: SCIENTIFIC INFORMATION
..........................................................................
28
PHARMACEUTICAL INFORMATION
.....................................................................
28
CLINICAL TRIALS
...............................